<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527954</url>
  </required_header>
  <id_info>
    <org_study_id>1412-ALC-086-PH</org_study_id>
    <nct_id>NCT02527954</nct_id>
  </id_info>
  <brief_title>Aneuploidies in Embryos and Spermatozoa From Patients With Y-chromosome Microdeletions</brief_title>
  <official_title>Impact of Y-chromosome Microdeletions From Infertile Men on the Chromosomal Constitution of Their Spermatozoa and Embryos. Combined IntraCytoplasmatic Sperm Injection (ICSI) and Preimplantation Genetic Screening (PGS) as Treatment Strategy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI Alicante</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IVI Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Igenomix</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI Alicante</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, investigators assess, using Fluorescence in situ Hybridization (FISH) and
      Comparative Genomic Hybridization (CGH) arrays for Preimplantation Genetic Screening (PGS),
      the incidence of aneuploidies in spermatozoa and embryos from infertile men with and without
      microdeletions who undergo assisted reproduction in their clinics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nowadays, Y-chromosome microdeletions are one of the most common causes of male infertility.
      With a frequency of 8-20% in non-obstructive azoospermic men and 3-14% in severe
      oligozoospermic men, is the most usual chromosome anomaly associated with failure in sperm
      production, although the frequency seems to change due to differences in the experimental
      designs, the ethnic differences, the genetic background, or even environmental influences.

      The absence of some genes located on certain regions in the long arm of the human Y
      chromosome, known as the azoospermia factor region (AZF), causes spermatogenic failure, while
      spermatozoa has been found in either the ejaculate or the testicle of most patients.
      Detection of deletions is crucial for the medical treatment of these patients, since it has a
      prognostic value in predicting potential success of testicular sperm retrieval in azoospermic
      patients with certain microdeletions, and allows avoiding invasive techniques in
      oligozoospermic patients whose sperm production could result in progressive worsening.

      The development of assisted reproduction techniques, such as intracytoplasmatic sperm
      injection (ICSI), together with testicular or epididymis sperm retrieval for azoospermic men
      has allowed these patients to become fathers using their own gametes. Although the effect of
      Y-chromosome microdeletions on ICSI outcome is controversial, the ability to vertically
      transmit that genetic defect, and so the infertility, to the offspring has been accepted.
      Until recently, no clinical consequences other than infertility were supposed in the
      ICSI-conceived sons of fathers with deletions. However, different studies in the last years,
      suggest other potentially risks transmitted to the offspring, such as the development of
      sexual dysfunction due to sex chromosome abnormalities (Turner or Klinefelter syndromes,
      etc.) or other somatic disorders with worse health implications caused by chromosome
      aberrations outside the AZF regions or in autosomes that has been associated to Y-chromosome
      microdeletions. No major clinical complications than infertility has been described in the
      offspring born from fathers with deletions to date, but it is important to remember that the
      first generation of those babies, mainly obtained by ICSI, has just reached maturity.
      Moreover, the mentioned chromosome anomalies, could stop embryo development or increase
      miscarriage rate. Few studies focused in the incidence of miscarriages in these couples but
      microdeletions have been detected more frequents in men from couples with recurrent pregnancy
      loss.

      In order to offer fully genetic counseling to these couples, further studies focusing on the
      relationship between Y-chromosome microdeletions and other chromosomal abnormalities, which
      also provide information about their consequences in their embryos, are required. Thus, the
      actual risk of transmitting different anomalies associated to microdeletions to those embryos
      will be clarified, increasing the chances of a successful pregnancy and live birth.

      In this study, investigators assess, using Fluorescence in situ Hybridization (FISH) and
      Comparative Genomic Hybridization (CGH) arrays for Preimplantation Genetic Screening (PGS),
      the incidence of aneuploidies in spermatozoa and embryos from infertile men with and without
      microdeletions who undergo assisted reproduction in their clinics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>% Embryos with aneuploidies</measure>
    <time_frame>three years</time_frame>
    <description>The incidence of embryonic aneuploidies will be examined by CGH arrays analysis after biopsy in day 3 or day 5 of embryo development. This technology allows the analysis of all the chromosomes, so both aneuploidies in gonosomes and autosomes will be determined.
To measure these percentages the images obtained after CGH array will be analyzed by BlueFuse Software (BlueGnome, Cambridge, UK), identifying normal euploid embryos, embryos with full or partial aneuploidy and chaotic embryos.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% Spermatozoa with aneuploidies</measure>
    <time_frame>Three years</time_frame>
    <description>The incidence of aneuploidy (%) in sperm will be examined by FISH, analyzing chromosomes 13, 18, 21, X and Y.
To measure these percentages two examiners will analyze 2000 spermatozoa in each sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate (%)</measure>
    <time_frame>three years</time_frame>
    <description>nº fertilized oocytes/ nº metaphase II oocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 3 embryos rate (%)</measure>
    <time_frame>Three years</time_frame>
    <description>nº embryos at day 3/ nº fertilized oocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blastocyst rate (%)</measure>
    <time_frame>Three years</time_frame>
    <description>nº blastocyst/ nº fertilized oocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cycle efficiency</measure>
    <time_frame>Four years</time_frame>
    <description>nº transferred embryos + vitrified embryos</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate (%)</measure>
    <time_frame>Four years</time_frame>
    <description>nº pregnancies/ nº embryos transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate (%)</measure>
    <time_frame>Four years</time_frame>
    <description>% of positive pregnancy tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate (%)</measure>
    <time_frame>Four years</time_frame>
    <description>nº pregnancies (proven by the presence of at least 1 embryo with cardiac activity positive by ultrasound after 5-6 weeks of development)/ nº of transfer cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate (%)</measure>
    <time_frame>Four years</time_frame>
    <description>nº gestational sacs/ nº transferred embryos</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abortion rate (%)</measure>
    <time_frame>Four years</time_frame>
    <description>nº miscarriages/ nº pregnancies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate (%)</measure>
    <time_frame>Four years</time_frame>
    <description>% clinical pregnancies that do not finish in abortion or ectopic pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate (%)</measure>
    <time_frame>Four years</time_frame>
    <description>Proportion of live birth at home per embryo transferred.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Male Sterility Due to Y-chromosome Deletions</condition>
  <arm_group>
    <arm_group_label>Infertile with Y-chromosome deletions</arm_group_label>
    <description>No intervention will be performed.
Couples whose infertile men has a Y-chromosome microdeletion (detected in blood cells by Polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infertile without Y-chromosome deletions</arm_group_label>
    <description>No intervention will be performed.
Couples whose infertile men has not any Y-chromosome microdeletion (detected in blood cells by polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 2)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, ejaculated semen or testicular biopsy, blastomere
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Couples undergoing &quot;In vitro&quot; Fertilization (IVF) treatment whose man has non-obstructive
        azoospermia or severe oligozoospermia (≤ 5x1000000 spermatozoa/ml) and consent the genetic
        analysis of semen samples, as well as the embryo cohort generated by ICSI.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Couples with male infertility whose man has non-obstructive azoospermia or severe
             oligozoospermia with ≤5x1000000 spermatozoa/ml.

          2. Assisted Reproductive Technology: ICSI with motile spermatozoa and PGS by CGH arrays.

          3. Women &lt;38 years if microinjection is carried out in their own eggs, or 38≤ age &lt;50
             years if they receive donated eggs.

          4. Women with body mass index (BMI)&lt;30.

          5. Men&lt;50 years

        Exclusion Criteria:

          1. Couples with abnormal karyotypes.

          2. Women with any uterine pathology or abnormality, hydrosalpinx, thrombophilia or
             systemic diseases at the time of embryo transfer that could prejudge the outcome of
             the cycle

          3. Couples with repeated miscarriages (≥2) or implantation failures (≥2).

          4. Couples whose men has obstructive azoospermia, genital tract infections (mumps,
             inflammation, varicocele), cryptorchidism, or if he receives any treatment that can
             reduce the sperm count.

          5. Seminal samples processed by Magnetic Activated Cell Sorting (MACS) technique.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Purificación Hernández-Vargas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Valenciano de Infertilidad, IVI Alicante</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Purificación Hernández-Vargas, PhD</last_name>
    <phone>+34 966 01 24 90</phone>
    <phone_ext>13129</phone_ext>
    <email>puri.hernandez@ivi.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilia Mateu, PhD</last_name>
    <phone>34 963905310</phone>
    <phone_ext>18527</phone_ext>
    <email>emilia.mateu@igenomix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IVI Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Purificación Hernández-Vargas, PhD</last_name>
      <phone>34 966 01 24 90</phone>
      <phone_ext>13129</phone_ext>
      <email>puri.hernandez@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Inmaculada Pérez-Cano, BsC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Munoz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Sellés, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Purificación Hernández, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IVI Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>03007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Mollá, PhD</last_name>
      <phone>.:+34 968 200 031</phone>
      <phone_ext>16569</phone_ext>
      <email>marta.molla@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Jose Landeras, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Mollá, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Igenomix</name>
      <address>
        <city>Valencia</city>
        <zip>41980</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Ferlin A, Arredi B, Speltra E, Cazzadore C, Selice R, Garolla A, Lenzi A, Foresta C. Molecular and clinical characterization of Y chromosome microdeletions in infertile men: a 10-year experience in Italy. J Clin Endocrinol Metab. 2007 Mar;92(3):762-70. Epub 2007 Jan 9.</citation>
    <PMID>17213277</PMID>
  </reference>
  <reference>
    <citation>Foresta C, Moro E, Ferlin A. Y chromosome microdeletions and alterations of spermatogenesis. Endocr Rev. 2001 Apr;22(2):226-39. Review.</citation>
    <PMID>11294825</PMID>
  </reference>
  <reference>
    <citation>Foresta C, Moro E, Ferlin A. Prognostic value of Y deletion analysis. The role of current methods. Hum Reprod. 2001 Aug;16(8):1543-7. Review.</citation>
    <PMID>11473940</PMID>
  </reference>
  <reference>
    <citation>Li Z, Haines CJ, Han Y. &quot;Micro-deletions&quot; of the human Y chromosome and their relationship with male infertility. J Genet Genomics. 2008 Apr;35(4):193-9. doi: 10.1016/S1673-8527(08)60027-2. Review.</citation>
    <PMID>18439975</PMID>
  </reference>
  <reference>
    <citation>Sadeghi-Nejad H, Farrokhi F. Genetics of azoospermia: current knowledge, clinical implications, and future directions. Part II: Y chromosome microdeletions. Urol J. 2007 Fall;4(4):192-206. Review.</citation>
    <PMID>18270942</PMID>
  </reference>
  <reference>
    <citation>Silber SJ. The Y chromosome in the era of intracytoplasmic sperm injection: a personal review. Fertil Steril. 2011 Jun 30;95(8):2439-48.e1-5. doi: 10.1016/j.fertnstert.2011.05.070. Review.</citation>
    <PMID>21704208</PMID>
  </reference>
  <reference>
    <citation>Suganthi R, Vijesh VV, Vandana N, Fathima Ali Benazir J. Y choromosomal microdeletion screening in the workup of male infertility and its current status in India. Int J Fertil Steril. 2014 Jan;7(4):253-66. Epub 2013 Dec 22. Review.</citation>
    <PMID>24520494</PMID>
  </reference>
  <reference>
    <citation>Choi JM, Chung P, Veeck L, Mielnik A, Palermo GD, Schlegel PN. AZF microdeletions of the Y chromosome and in vitro fertilization outcome. Fertil Steril. 2004 Feb;81(2):337-41.</citation>
    <PMID>14967370</PMID>
  </reference>
  <reference>
    <citation>Kihaile PE, Kisanga RE, Aoki K, Kumasako Y, Misumi J, Utsunomiya T. Embryo outcome in Y-chromosome microdeleted infertile males after ICSI. Mol Reprod Dev. 2004 Jun;68(2):176-81.</citation>
    <PMID>15095338</PMID>
  </reference>
  <reference>
    <citation>Liu XH, Qiao J, Li R, Yan LY, Chen LX. Y chromosome AZFc microdeletion may not affect the outcomes of ICSI for infertile males with fresh ejaculated sperm. J Assist Reprod Genet. 2013 Jun;30(6):813-9. doi: 10.1007/s10815-013-0009-y. Epub 2013 May 30.</citation>
    <PMID>23715876</PMID>
  </reference>
  <reference>
    <citation>Mulhall JP, Reijo R, Alagappan R, Brown L, Page D, Carson R, Oates RD. Azoospermic men with deletion of the DAZ gene cluster are capable of completing spermatogenesis: fertilization, normal embryonic development and pregnancy occur when retrieved testicular spermatozoa are used for intracytoplasmic sperm injection. Hum Reprod. 1997 Mar;12(3):503-8.</citation>
    <PMID>9130751</PMID>
  </reference>
  <reference>
    <citation>Oates RD, Silber S, Brown LG, Page DC. Clinical characterization of 42 oligospermic or azoospermic men with microdeletion of the AZFc region of the Y chromosome, and of 18 children conceived via ICSI. Hum Reprod. 2002 Nov;17(11):2813-24.</citation>
    <PMID>12407032</PMID>
  </reference>
  <reference>
    <citation>Patrat C, Bienvenu T, Janny L, Faure AK, Fauque P, Aknin-Seifer I, Davy C, Thiounn N, Jouannet P, Lévy R. Clinical data and parenthood of 63 infertile and Y-microdeleted men. Fertil Steril. 2010 Feb;93(3):822-32. doi: 10.1016/j.fertnstert.2008.10.033. Epub 2008 Dec 4.</citation>
    <PMID>19062004</PMID>
  </reference>
  <reference>
    <citation>Stouffs K, Lissens W, Tournaye H, Van Steirteghem A, Liebaers I. The choice and outcome of the fertility treatment of 38 couples in whom the male partner has a Yq microdeletion. Hum Reprod. 2005 Jul;20(7):1887-96. Epub 2005 Mar 24.</citation>
    <PMID>15790609</PMID>
  </reference>
  <reference>
    <citation>van Golde RJ, Wetzels AM, de Graaf R, Tuerlings JH, Braat DD, Kremer JA. Decreased fertilization rate and embryo quality after ICSI in oligozoospermic men with microdeletions in the azoospermia factor c region of the Y chromosome. Hum Reprod. 2001 Feb;16(2):289-92.</citation>
    <PMID>11157822</PMID>
  </reference>
  <reference>
    <citation>Wu W, Zhou ZM, Lin M, Mao YD, Wang W, Yang XY, Liu JY. [Y-chromosome microdeletions do not affect the outcomes of ICSI for infertile males]. Zhonghua Nan Ke Xue. 2011 Sep;17(9):771-4. Chinese.</citation>
    <PMID>21961234</PMID>
  </reference>
  <reference>
    <citation>Patsalis PC, Sismani C, Quintana-Murci L, Taleb-Bekkouche F, Krausz C, McElreavey K. Effects of transmission of Y chromosome AZFc deletions. Lancet. 2002 Oct 19;360(9341):1222-4.</citation>
    <PMID>12401251</PMID>
  </reference>
  <reference>
    <citation>Patsalis PC, Skordis N, Sismani C, Kousoulidou L, Koumbaris G, Eftychi C, Stavrides G, Ioulianos A, Kitsiou-Tzeli S, Galla-Voumvouraki A, Kosmaidou Z, Hadjiathanasiou CG, McElreavey K. Identification of high frequency of Y chromosome deletions in patients with sex chromosome mosaicism and correlation with the clinical phenotype and Y-chromosome instability. Am J Med Genet A. 2005 Jun 1;135(2):145-9.</citation>
    <PMID>15880425</PMID>
  </reference>
  <reference>
    <citation>Siffroi JP, Le Bourhis C, Krausz C, Barbaux S, Quintana-Murci L, Kanafani S, Rouba H, Bujan L, Bourrouillou G, Seifer I, Boucher D, Fellous M, McElreavey K, Dadoune JP. Sex chromosome mosaicism in males carrying Y chromosome long arm deletions. Hum Reprod. 2000 Dec;15(12):2559-62.</citation>
    <PMID>11098026</PMID>
  </reference>
  <reference>
    <citation>Dewan S, Puscheck EE, Coulam CB, Wilcox AJ, Jeyendran RS. Y-chromosome microdeletions and recurrent pregnancy loss. Fertil Steril. 2006 Feb;85(2):441-5.</citation>
    <PMID>16595224</PMID>
  </reference>
  <reference>
    <citation>Jorgez CJ, Weedin JW, Sahin A, Tannour-Louet M, Han S, Bournat JC, Mielnik A, Cheung SW, Nangia AK, Schlegel PN, Lipshultz LI, Lamb DJ. Aberrations in pseudoautosomal regions (PARs) found in infertile men with Y-chromosome microdeletions. J Clin Endocrinol Metab. 2011 Apr;96(4):E674-9. doi: 10.1210/jc.2010-2018. Epub 2011 Jan 20.</citation>
    <PMID>21252244</PMID>
  </reference>
  <reference>
    <citation>Mateu E, Rodrigo L, Martínez MC, Peinado V, Milán M, Gil-Salom M, Martínez-Jabaloyas JM, Remohí J, Pellicer A, Rubio C. Aneuploidies in embryos and spermatozoa from patients with Y chromosome microdeletions. Fertil Steril. 2010 Dec;94(7):2874-7. doi: 10.1016/j.fertnstert.2010.06.046. Epub 2010 Jul 24.</citation>
    <PMID>20655521</PMID>
  </reference>
  <reference>
    <citation>Page DC, Silber S, Brown LG. Men with infertility caused by AZFc deletion can produce sons by intracytoplasmic sperm injection, but are likely to transmit the deletion and infertility. Hum Reprod. 1999 Jul;14(7):1722-6.</citation>
    <PMID>10402375</PMID>
  </reference>
  <reference>
    <citation>Perrin A, Douet-Guilbert N, Laudier B, Couet ML, Guérif F, Royère D, Le Bris MJ, De Braekeleer M, Morel F. Meiotic segregation in spermatozoa of a 45,XY,-14,der(18)t(14;18)(q11;p11.3) translocation carrier: a case report. Hum Reprod. 2007 Mar;22(3):729-32. Epub 2006 Oct 24.</citation>
    <PMID>17062581</PMID>
  </reference>
  <reference>
    <citation>Yogev L, Segal S, Zeharia E, Gamzu R, Maymon BB, Paz G, Botchan A, Hauser R, Yavetz H, Kleiman SE. Sex chromosome alignment at meiosis of azoospermic men with azoospermia factor microdeletion. J Androl. 2004 Jan-Feb;25(1):110-6.</citation>
    <PMID>14662793</PMID>
  </reference>
  <reference>
    <citation>Martínez MC, Bernabé MJ, Gómez E, Ballesteros A, Landeras J, Glover G, Gíl-Salom M, Remohí J, Pellicer A. Screening for AZF deletion in a large series of severely impaired spermatogenesis patients. J Androl. 2000 Sep-Oct;21(5):651-5.</citation>
    <PMID>10975411</PMID>
  </reference>
  <reference>
    <citation>Oliva R, Margarit E, Ballescá JL, Carrió A, Sánchez A, Milà M, Jiménez L, Alvarez-Vijande JR, Ballesta F. Prevalence of Y chromosome microdeletions in oligospermic and azoospermic candidates for intracytoplasmic sperm injection. Fertil Steril. 1998 Sep;70(3):506-10.</citation>
    <PMID>9757880</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>September 4, 2017</last_update_submitted>
  <last_update_submitted_qc>September 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Valenciano de Infertilidad, IVI Alicante</investigator_affiliation>
    <investigator_full_name>Purificación Hernández</investigator_full_name>
    <investigator_title>Research Coordinator</investigator_title>
  </responsible_party>
  <keyword>Y-chromosome microdeletions</keyword>
  <keyword>aneuploidy</keyword>
  <keyword>embryos</keyword>
  <keyword>spermatozoa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneuploidy</mesh_term>
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Chromosome Deletion</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
    <mesh_term>Sex Chromosome Aberrations</mesh_term>
    <mesh_term>Sex Chromosome Disorders of Sex Development</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

